Tagemtricitabine

Trans and cis women and men all have similar levels of PrEP drugs in blood

T

nam/aidsmap, 7 September 2020 A study in which 24 trans women and 24 trans men who were taking gender-affirming hormone therapy were directly observed to take a daily dose of the standard formulation of the HIV prevention medication PrEP found that the levels of the two PrEP drugs tenofovir and emtricitabine were similar to the levels seen in similar cis men and women, and were all above levels...

Information about TRUVADA and ATRIPLA delisting

I

Australian Federation of AIDS Organisations (AFAO), March 30th 2020 From 1 April 2020 Truvada for HIV treatment and for pre-exposure prophylaxis (PrEP) will no longer be available through the Pharmaceutical Benefits Scheme (PBS). There are alternatives to Truvada for PrEP in Australia. Community members eligible for PrEP can access generic versions of Truvada supplied by Apotex, Mylan and Lupin...

Transgender women taking PrEP have lower levels of PrEP drugs than cisgender men

T

aidsmap/nam, November 9th 2018 A study presented at October’s HIV Research for Prevention conference (HIVR4P) in Madrid shows that transgender women who are taking feminising hormones and also taking pre-exposure prophylaxis (PrEP) have levels of the PrEP drugs tenofovir and emtricitabine in their blood that are about 25% lower than those in cisgender men, and levels in rectal tissue cells...

HIV PrEP available on PBS in Australia from 1 April / Links to Clinical Resources

H

Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM), 21 March 2018 ASHM congratulates the Federal Health Minister, the Hon. Greg Hunt’s announcement of a landmark in HIV prevention to approve HIV-prevention drugs – tenofovir with emtricitabine, known as PrEP – on the Pharmaceutical Benefits Scheme from 1 April, thereby providing broader access for any doctor or general...

Expanded HIV PrEP implementation in communities in NSW (EPIC-NSW): design of an open label, single arm implementation trial

E

BMC Public Health   Published: 2 February 2018 Abstract: Background The New South Wales (NSW) HIV Strategy 2016–2020 aims for the virtual elimination of HIV transmission in NSW, Australia, by 2020. Despite high and increasing levels of HIV testing and treatment since 2012, the annual number of HIV diagnoses in NSW has remained generally unchanged. Pre-exposure prophylaxis (PrEP) is highly...

The updated 2017 ASHM HIV pre-exposure prophylaxis (PrEP) Guidelines

T

Journal of Virus Eradication, 2017; 3: 168–184 Daily use of co-formulated tenofovir and emtricitabine for HIV pre-exposure prophylaxis (PrEP) by populations at high risk of HIV infection is now recommended in guidelines from the United States, Europe and Australia and globally through the 2015 WHO guidelines.  These 2017 Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine‘s...

Welcome to SASHA

SASHA is a current awareness service with news and views on various aspects of sexual health and sexuality, from a wide range of sources. These range from credible sources of sexual health and related information, to relevant opinion pieces in the media.

Categories